denecimig (Mim8) - Hematologic The Deep dive section features an analysis for select pipeline drugs that are expected to be FDA-approved in the upcoming quarters. Selected agents are expected to...

New report, an evolution of previous DEI reports, aims to demonstrate transparency and accountability for company’s corporate social responsibility journey

Grant helps provide a home away from home for families facing cancer

In its annual fall report dedicated to oncology, Prime Therapeutics highlights strategies to improve outcomes, reduce costs and support patients — starting with a bold approach to managing cancer care

Prime is committed to simplifying the cancer care journey through leading oncology solutions designed to support people with cancer

Payne to integrate communications, government affairs and policy efforts at leading purpose-driven, transparent PBM

How Prime Therapeutics/Magellan Rx Management reimagines pharmacy to do what's right.

The event emphasizes additional measures for obesity therapy.

Prime Therapeutics experts share more about the latest in precision oncology, including barriers to treatment and the current regulatory landscape

Prime Therapeutics helps simplify the cancer care journey and manage drug costs through leading oncology solutions

At Pharmacy Benefit Management Institute (PBMI) annual conference, Prime received two awards: one for cost savings, another for leadership.

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

Magellan Rx first to innovate with Medicaid VBC solutions for states grappling with the high cost of novel cell and gene therapies

Prime Therapeutics/Magellan Rx Management's signature event featured the hottest topics in specialty drug management and more

Prime Therapeutics is committed to simplifying the patient journey for those with complex conditions through its industry-leading HighTouchRx product

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

Formulary design recommendations help create competition to drive savings, provide optionality to meet unique client needs.

Event features discussions about health care industry trends, best practices and innovations

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

Prime Therapeutics clinical experts shared insights on the specialty drug pipeline at recent industry event

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Stories, perspectives and news coverage of Prime Therapeutics/Magellan Rx from AMCP 2024

Prime Therapeutics researchers share how the model helps to optimize drug therapy and lower costs

Abby Kim, PharmD, BCOP, is a senior director, clinical strategy and oncology specialty solutions, shares key takeaways from the American Journal of Managed Care (AJMC) forum, “Bridging evidence and...

A look at the specialty landscape and how Prime delivers value to employers

Prime Therapeutics offers innovative medication management solutions, supports patients with chronic conditions

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

Cover image for Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends Prime simplifies the cancer care pathway through innovative solutions that help manage complex...

From new treatment options for dry eye disease to type 2 diabetes, here are a few of the top U.S. Food and Drug Administration drug decisions expected this year

In the latest episode of the “Pharmacy Friends” podcast, hear more about what faster drug decisions could mean for evidence review, affordability assessment and implementation planning

Prime works to simplify medication management and support patients with migraine, making migraine treatment less of a pain point

Managed Markets Insight & Technology (MMIT)

Table view Editor-in-chief's message Year 2024 2025 2026 2027 2028 Projected Yearly U.S. Sales $0 $82 $177 $258 $311 The pipeline drug list is an aerial outline of drugs with anticipated FDA...

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

Submitted supplemental drugs Phase 3 supplemental drugs arimoclomol oral Name Manufacturer Clinical Use Dosage Form Development Status camrelizumab Jiangsu Hengrui HCC (unresectable, 1st-line, in...

Drug Generic Name Therapeutic category July2024 Pipeline - Total US sales for 2028 (Dollars in millions) botaretigene sparoparvovec Ophthalmology / Gene therapy $158 crinecerfont Endocrine $325...

Dosage and administration In the VISIONARY trial, sibeprenlimab was administered SC at a dose of 400 mg every 4 weeks and can be self-administered. Place in therapy IgAN, also known as Berger’s...

Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision aflibercept (Eylea HD) 8 mg Regeneron Macular edema from RVO (8 mg dose) Intravitreal sNDA – PR Oct-Dec...